about
Therapeutic Targeting of TelomeraseTherapeutic targeting of replicative immortalityHigh-efficiency Generation of Multiple Short Noncoding RNA in B-cells and B-cell-derived Extracellular Vesicles.Telomerase as a Cancer Target. Development of New MoleculesChemistry in human telomere biology: structure, function and targeting of telomere DNA/RNA.Recent advances on skin-resident stem/progenitor cell functions in skin regeneration, aging and cancers and novel anti-aging and cancer therapies.Generation of more effective cancer vaccinesAdvances in the molecular design of potential anticancer agents via targeting of human telomeric DNA.Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one.Prospects and challenges of building a cancer vaccine targeting telomeraseGeneration in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs.Telomerase as a universal tumor antigen for cancer vaccines.Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications.Targeting telomerase in hematologic malignancy.Novel Oligopyrrole Carboxamide based Nickel(II) and Palladium(II) Salens, Their Targeting of Human G-Quadruplex DNA, and Selective Cancer Cell Toxicity.A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer.
P2860
Q26741736-7E3D31A9-12C9-4A4A-87FD-381FACE794F0Q27027457-19BD1213-FC26-4378-AA11-587ADE4EA171Q27317402-D109292A-AA1D-4EEF-83EE-0DD946B0F39DQ28079188-39C5C58A-6928-470C-A890-DA38E5328FDCQ33814333-207A838A-7A9E-4F5D-B39A-D5031B96CC64Q34044908-0FB5AF55-2266-4673-B488-954FF0C297BEQ34169981-5593129B-9CB1-4DFE-A597-E5889EDEACCDQ34413414-835D86FA-1579-4C31-B351-9297B8B2F6CBQ35886889-E302CCD1-1FF5-4EAE-B834-1137CEA6F017Q36918394-389EA0CC-83E6-46C9-B383-BB9A086DB71CQ37173478-624CDF37-674A-4DF0-944A-138E640C4A2CQ37259573-3F8C3279-0287-4FCD-B988-4F9F11B86637Q37310063-2379DAF7-4BF5-4275-8BAC-00EC372D0CB1Q37750789-A9946630-020B-4627-ADD5-60DB52E0D3B8Q49061522-49FA6C65-225E-4605-8568-CA12587DCC70Q51065162-4A76DEE7-E36C-4E37-B31D-37952AB8AAC7
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Telomerase immunity from bench to bedside: round one.
@ast
Telomerase immunity from bench to bedside: round one.
@en
type
label
Telomerase immunity from bench to bedside: round one.
@ast
Telomerase immunity from bench to bedside: round one.
@en
prefLabel
Telomerase immunity from bench to bedside: round one.
@ast
Telomerase immunity from bench to bedside: round one.
@en
P2860
P921
P356
P1476
Telomerase immunity from bench to bedside: round one.
@en
P2093
Maurizio Zanetti
Xochtil Cortez-Gonzalez
P2860
P2888
P356
10.1186/1479-5876-5-12
P577
2007-02-26T00:00:00Z
P5875
P6179
1030171784